Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Oct.  07, 2019  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock. All of the above-described awards were made under the GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

GBT Announces New Employment Inducement Grants.

SOUTH SAN FRANCISCO, Calif., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD) research have been accepted for oral and poster presentations during the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention in Baltimore, taking place October 9-12, 2019. Additionally, GBT will host a lunch symposium at the conference, “Sickle Cell Disease and Brain Health,” at 11:45 a.m. ET on Friday, October 11. The symposium will focus on helping attendees understand how SCD impacts neurocognition and the function of the brain over a patient’s lifetime.

GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention

Voxelotor’s NDA was granted Priority Review status that cuts the FDA review time to six months. The PDUFA date is set for February 26th, 2020.

Global Blood Therapeutics: Stock Responds To Voxelotor Receiving Priority Review

The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.

FDA Grants Priority Review to Global Blood's SCD Candidate

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Why Is Global Blood (GBT) Up 6.2% Since Last Earnings Report?

The company's most advanced drug has taken a step toward FDA approval.

Why Global Blood Therapeutics Stock Jumped 10.9% Today

Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months

GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019, at 2:50 p.m. Eastern Time.

GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference

Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.

Global Blood Focuses on Lead Candidate Amid Competition

Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD

GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Voxelotor can prove to be a blockbuster opportunity.

Global Blood Therapeutics: A Promising Biotech Pick In 2019

I take a closer look into Global Blood Therapeutic's voxelotor phase 3 data in sickle cell disease as detailed by a recent New England Journal of Medicine article.

The Totality Of Voxelotor Phase 3 Data Increases My Conviction In Global Blood Therapeutics

Global Blood Therapeutics reported encouraging Phase III results for Voxelotor in Sickle Cell Disease. I provide 3 reasons why I am buying the stock after the recent results.

Global Blood Therapeutics: My 3 Reasons For A Buy

Raining over the barren desert of sickle cell disease, voxelotor demonstrated its prowess in the HOPE trial via improvement in hemoglobin, reticulocytes count, indirect bilirubin, and painful crisis.

Global Blood Therapeutics: Raining In The Desert With Voxelotor

The company reported positive Phase III clinical results of Voxelotor showing a significant hemoglobin improvement compared to placebo.

Global Blood Therapeutics: Voxelotor Can Take The Stock Price To New All-Time Highs

AeroVironment

BlackBerry

Find out how earnings hurt some of these stocks.

Why BlackBerry, AeroVironment, and Global Blood Therapeutics Slumped Today

BioMarin Pharmaceutical

Dicerna Pharmaceuticals

Iovance Biotherapeutics

Krystal Biotech

We are now approaching the second half of 2019. And it may be time for a little portfolio rebalancing.

5 Strong Buy Biotech Stocks for the Second Half

Global Blood Therapeutics obtains positive results from its phase 3 study using Voxelotor to treat patients with sickle cell disease.

Global Blood Therapeutics' Data Falls On Deaf Ears, But Massive Potential Exists With Accelerated Approval Pathway

Updated data from a late-stage trial of voxelotor fell shy of investors' expectations.

Global Blood's Sickle Cell Treatment Fails to Impress

Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Global Blood Therapeutics (GBT) Stock

Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.

A Biotech Stock to Watch Now

Why Is Global Blood (GBT) Up 2% Since Last Earnings Report?

Global Blood Therapeutics (GBT) remains on track for Voxelotor commercialization in 2020.

Global Blood Remains On Track For Transformational Year

Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

Global Blood is fast progressing on the development plans for its lead pipeline candidate, voxelotor for the treatment of sickle cell disease.

News for Global Blood Therapeutics Stock (GBT)